» Articles » PMID: 29321371

Assessing Drug Efficacy Against Plasmodium Falciparum Liver Stages in Vivo

Abstract

Malaria eradication necessitates new tools to fight the evolving and complex Plasmodium pathogens. These tools include prophylactic drugs that eliminate Plasmodium liver stages and consequently prevent clinical disease, decrease transmission, and reduce the propensity for resistance development. Currently, the identification of these drugs relies on in vitro P. falciparum liver stage assays or in vivo causal prophylaxis assays using rodent malaria parasites; there is no method to directly test in vivo liver stage activity of candidate antimalarials against the human malaria-causing parasite P. falciparum. Here, we use a liver-chimeric humanized mouse (FRG huHep) to demonstrate in vivo P. falciparum liver stage development and describe the efficacy of clinically used and candidate antimalarials with prophylactic activity. We show that daily administration of atovaquone-proguanil (ATQ-PG; ATQ, 30 mg/kg, and PG, 10 mg/kg) protects 5 of 5 mice from liver stage infection, consistent with the use in humans as a causal prophylactic drug. Single-dose primaquine (60 mg/kg) has similar activity to that observed in humans, demonstrating the activity of this drug (and its active metabolites) in FRG huHep mice. We also show that DSM265, a selective Plasmodial dihydroorotate dehydrogenase inhibitor with causal prophylactic activity in humans, reduces liver stage burden in FRG huHep mice. Finally, we measured liver stage-to-blood stage transition of the parasite, the ultimate readout of prophylactic activity and measurement of infective capacity of parasites in the liver, to show that ATQ-PG reduces blood stage patency to below the limit of quantitation by quantitative PCR (qPCR). The FRG huHep model, thus, provides a platform for preclinical evaluation of drug candidates for liver stage causal prophylactic activity, pharmacokinetic/pharmacodynamics studies, and biological studies to investigate the mechanism of action of liver stage active antimalarials.

Citing Articles

Structure-Based Discovery and Development of Highly Potent Dihydroorotate Dehydrogenase Inhibitors for Malaria Chemoprevention.

Nie Z, Bonnert R, Tsien J, Deng X, Higgs C, El Mazouni F J Med Chem. 2024; 68(1):590-637.

PMID: 39710971 PMC: 11726676. DOI: 10.1021/acs.jmedchem.4c02394.


Novel hydrazone compounds with broad-spectrum antiplasmodial activity and synergistic interactions with antimalarial drugs.

Rosado-Quinones A, Colon-Lorenzo E, Pala Z, Bosch J, Kudyba K, Kudyba H Antimicrob Agents Chemother. 2024; 68(6):e0164323.

PMID: 38639491 PMC: 11620517. DOI: 10.1128/aac.01643-23.


Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention.

Burgert L, Reiker T, Golumbeanu M, Mohrle J, Penny M PLOS Glob Public Health. 2023; 2(3):e0000211.

PMID: 36962305 PMC: 10021282. DOI: 10.1371/journal.pgph.0000211.


Assessment of the drugability of initial malaria infection through miniaturized sporozoite assays and high-throughput screening.

Miglianico M, Bolscher J, Vos M, Koolen K, de Bruijni M, Rajagopal D Commun Biol. 2023; 6(1):216.

PMID: 36823266 PMC: 9950425. DOI: 10.1038/s42003-023-04599-3.


A pharmacokinetic-pharmacodynamic model for chemoprotective agents against malaria.

Cherkaoui-Rbati M, Andenmatten N, Burgert L, Egbelowo O, Fendel R, Fornari C CPT Pharmacometrics Syst Pharmacol. 2022; 12(1):50-61.

PMID: 36412499 PMC: 9835136. DOI: 10.1002/psp4.12875.


References
1.
Sulyok M, Ruckle T, Roth A, Murbeth R, Chalon S, Kerr N . DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017; 17(6):636-644. PMC: 5446410. DOI: 10.1016/S1473-3099(17)30139-1. View

2.
Miotto O, Almagro-Garcia J, Manske M, MacInnis B, Campino S, Rockett K . Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013; 45(6):648-55. PMC: 3807790. DOI: 10.1038/ng.2624. View

3.
Vaughan A, Mikolajczak S, Camargo N, Lakshmanan V, Kennedy M, Lindner S . A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol Biochem Parasitol. 2012; 186(2):143-7. DOI: 10.1016/j.molbiopara.2012.10.004. View

4.
Gujjar R, El Mazouni F, White K, White J, Creason S, Shackleford D . Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem. 2011; 54(11):3935-49. PMC: 3124361. DOI: 10.1021/jm200265b. View

5.
White N, Pukrittayakamee S, Phyo A, Rueangweerayut R, Nosten F, Jittamala P . Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med. 2014; 371(5):403-10. PMC: 4143746. DOI: 10.1056/NEJMoa1315860. View